Patel I H, Levy R H
Epilepsia. 1975 Dec;16(5):717-30. doi: 10.1111/j.1528-1157.1975.tb04756.x.
Three types of chronic-dosing experiments were implemented in a group of chronically catheterized male rhesus monkeys: Study I, constant rate infusion; Study II, infusion at three consecutive rates with priming doses; and Study III, oral multiple dosing at two consecutive levels with priming doses. Zero-order infusion rates and priming and maintenance doses were calculated for each animal using individual single-dose pharmacokinetic parameters. Ethosuximide was measured in plasma and urine by GLC. Experimental and predicted plasma and urine levels were in good agreement for all three studies. Total body clearance (Studies I and II) and elimination half-life (Studies I, II, and III) were not significantly different from their respective single-dose values. Excretion rate was proportional to infusion rate (Study II) and maintenance dose (Study III). It was established that in the case of ethosuximide in monkey, pharmacokinetic parameters derived from single-dose studies can be used to predict multiple-dosing schedules.
研究I,恒速输注;研究II,以三个连续速率输注并给予负荷剂量;研究III,以两个连续水平口服多次给药并给予负荷剂量。使用个体单剂量药代动力学参数为每只动物计算零级输注速率以及负荷剂量和维持剂量。通过气相色谱法测定血浆和尿液中的乙琥胺。在所有三项研究中,实验测得的和预测的血浆及尿液水平吻合良好。总体清除率(研究I和II)和消除半衰期(研究I、II和III)与各自的单剂量值相比无显著差异。排泄率与输注速率(研究II)和维持剂量(研究III)成正比。已证实,对于猴子体内的乙琥胺,单剂量研究得出的药代动力学参数可用于预测多次给药方案。